« Back
Home /
ACY-738

ACY-738

Item no.	HY-19327-50mg
Manufacturer	MedChem Express
CASRN	1375465-91-0
Amount	50 mg
Quantity options	100 mg 10mM/1mL 10 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.92
Formula	C14H14N4O2
Citations	[1]Jochems J, et al. Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability. Neuropsychopharmacology. 2014 Jan;39(2):389-400.<br>[2]Regna NL, et al. Specific HDAC6 inhibition by ACY-738 reduces SLE pathogenesis in NZB/W mice. Clin Immunol. 2016 Jan;162:58-73.<br>[3]Mithraprabhu S, et al. Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC. Br J Haematol. 2013 Aug;162(4):559-62.
Smiles	O=C(NO)C(C=N1)=CN=C1NC2(CC2)C3=CC=CC=C3
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	1375465-91-0
Available
Product Description	ACY-738 is a potent, selective and orally-bioavailable HDAC6 inhibitor, with an IC50 of 1.7 nM; ACY-738 also inhibits HDAC1, HDAC2, and HDAC3, with IC50s of 94, 128, and 218 nM.
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-programmed cell death
MolecularWeight	270.29
Clinical_Information	No Development Reported
Manufacturers Research Area	Cancer
Solubility	DMSO : ≥ 32 mg/mL
Manufacturers Target	HDAC
Isoform	HDAC1; HDAC2; HDAC3; HDAC6
Pathway	Cell Cycle/DNA Damage; Epigenetics

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-19327-50mg-safety-datasheet.pdf